Roche Wins U.S. Approval for New Oral Breast Cancer Drug
BASEL, Switzerland — November 17, 2026 — Swiss pharmaceutical company Roche has secured a significant regulatory victory in the United States after the Food and Drug Administration (FDA) authorized its new oral cancer medicine, Wilserdly, for a specific group of patients with advanced breast cancer. The decision gives the company an opportunity to strengthen its…
